Zealand Pharma AS 2024 AR2
The report highlights Zealand Pharma's transformational year in 2024, marked by significant clinical progress in its obesity portfolio, including the initiation of a Phase 2b trial for petrelintide. The company substantially strengthened its financial position by raising DKK 8.5 billion in gross proceeds through two capital raises. Additionally, Zealand Pharma launched its first dedicated sustainability strategy focusing on patients, people, and operations, and developed a Climate Change Transition Plan aligned with the Paris Agreement. Despite regulatory hurdles for its rare disease assets, the company expanded its workforce by 30% while maintaining high employee engagement.
Company: Zealand Pharma AS
Sector: Health Care
Country: Denmark
Year: 2024
Type: AR2
Pages: 193
Zealand Pharma AS
Annual Report
The report highlights Zealand Pharma's transformational year in 2024, marked by significant clinical progress in its obesity portfolio, including the initiation of a Phase 2b trial for petrelintide. The company substantially strengthened its financial position by raising DKK 8.5 billion in gross proceeds through two capital raises. Additionally, Zealand Pharma launched its first dedicated sustainability strategy focusing on patients, people, and operations, and developed a Climate Change Transition Plan aligned with the Paris Agreement. Despite regulatory hurdles for its rare disease assets, the company expanded its workforce by 30% while maintaining high employee engagement.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees